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X-linked Charcot–Marie–Tooth disease (CMT1X) is the second most common inherited neuropathy, caused by mutations in gap
junction beta-1 (GJB1). Males have a uniformly moderately severe phenotype while females have a variable phenotype, suggested to
be due to X inactivation. We aimed to assess X inactivation pattern in females with CMT1X and correlate this with phenotype using
the CMT examination score to determine whether the X inactivation pattern accounted for the variable phenotype in females with
CMT1X. We determined X inactivation pattern in 67 females with CMT1X and 24 controls using the androgen receptor assay. We were
able to determine which X chromosome carried the GJB1 mutation in 30 females. There was no diﬀerence in X inactivation pattern
between patients and controls. In addition, there was no correlation between X inactivation pattern in blood and phenotype. A possible
explanation for these ﬁndings is that the X inactivation pattern in Schwann cells rather than in blood may explain the variable phenotype
in females with CMT1X.
 2012 Elsevier B.V. All rights reserved.
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X-linked Charcot–Marie–Tooth disease (CMT1X),
caused by mutations in the gap junction beta-1 gene
(GJB1), is the second most frequent cause of CMT [1,2].
Over 300 diﬀerent mutations have been described in GJB1
to date, spread throughout the coding region. Several muta-
tions have also been described outside the coding region, in0960-8966/$ - see front matter  2012 Elsevier B.V. All rights reserved.
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E-mail address: sinead.murphy@amnch.ie (S.M. Murphy).the promoter or untranslated regions of the gene, resulting
in a similar phenotype as coding region mutations [3,4].
Males have a relatively uniform phenotype, presenting
within the ﬁrst two decades with diﬃculty walking, distal
weakness and sensory loss. Severity increases with age, such
that most men are moderately to severely aﬀected by adult-
hood; this suggests that all mutations cause a loss of
function of the connexin32 protein [5]. However, we previ-
ously demonstrated that females carrying a GJB1 mutation
have a variable phenotype; approximately two-thirds have a
mild non-progressive phenotype, one-third have a moder-
ately severe phenotype that progresses with age, and a small
proportion are asymptomatic [6]. This variable phenotype
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Fig. 1. Bar chart demonstrating the ratio of one allele to the other in
females with GJB1 mutations and controls, e.g., 15% of patients and
16.6% of controls had a ratio of one allele to the other of between 10:90
and 20:80.
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tivation [6–8].
X inactivation occurs early in embryonic development
whereby either the paternally- or maternally-inherited X
chromosome is inactivated in each cell. This ensures equiv-
alent expression of sex chromosome genes in males and
females [9]. Once X inactivation has occurred in a cell, all
subsequent daughter cells have the same X inactivation
pattern. The process is usually random such that roughly
equal amounts of cells express each X chromosome. In
the general population X inactivation pattern is normally
distributed; 10–20% of females have a skewed X inactiva-
tion patternP 80:20 [10,11]. However, carrying a mutation
in some X-linked genes has been shown to aﬀect X inacti-
vation pattern [12–14].
We previously investigated X inactivation pattern in 14
females with GJB1 mutations and found no diﬀerence in X
inactivation pattern between patients and controls [6];
however, we could not determine which X chromosome
carried the mutation and thus were unable to correlate X
inactivation pattern with phenotype. In this study, we
determined the X inactivation pattern in a large cohort of
females and family members carrying GJB1 mutations to
investigate whether X inactivation pattern correlates with
phenotype.
2. Materials and methods
This studywas approved by theResearchEthics Commit-
tee at the National Hospital for Neurology and Neurosur-
gery and the Wayne State University Human Investigation
Committee. All patients gave written informed consent to
undergo genetic testing.
Females with CMT1X and, where possible, their
aﬀected male relatives were recruited. The severity of neu-
ropathy was assessed using the CMT Neuropathy Score
(CMTNS) [15]. A total score of 0–10 indicates mild sever-
ity; 11–20 moderate severity and P21 severe neuropathy.
Where neurophysiological testing was unavailable the
CMT Examination Score (CMTES), a subscore of the
CMTNS, was used.
We determined the X inactivation pattern in blood using
the androgen receptor assay as we have described previ-
ously [6]. In brief, >90% of females have a polymorphic
CAG repeat region within the androgen receptor gene on
the X chromosome [11]. Two CCGG sites 100 bp upstream
of this CAG repeat region are methylated on the inactive X
chromosome. A restriction digest was performed in females
using a methylation sensitive enzyme HpaII which cleaves
the active X chromosomes at the unmethylated CCGG
sites, leaving the inactive X chromosomes intact. PCR
was then performed to amplify this region on the inactive
X chromosomes. Size analysis of the PCR products was
then performed to determine the ratio of one allele to the
other. The terms short and long allele are used (referring
to the size of the CAG repeat) to distinguish between one
allele and the other.The ratio of one allele to the other was plotted against
the proportion of individuals (patients and controls) to
compare X inactivation in patients and controls.
In order to determine whether X inactivation pattern
varied by age, we grouped patients into three groups:
<30 years, 31–60 years and >60 years. ANOVA was used
to compare X inactivation pattern between the three
groups.
In order to determine which X chromosome was carry-
ing the GJB1 mutation, and hence the proportion of
mutant allele that was active, we determined the common
allele carried by aﬀected family members by using the num-
ber of CAG repeats on each allele.
The proportion of mutant allele that was active was
plotted against the CMTES and Pearson correlation coef-
ﬁcient calculated to determine whether there was any rela-
tionship between X inactivation pattern in blood and
phenotype.
3. Results
X inactivation pattern was determined in 67 females
with CMT1X (mean age 46 years, range 18–78), 18 aﬀected
male relatives and 24 female controls (mean age 51 years,
range 23–70). The proportion of long allele active ranged
from 3.56% to 97.32% in patients and 2.07% to 84.31%
in controls. There was no diﬀerence in X inactivation pat-
tern between females with a GJB1 mutation and controls
(Fig. 1).
There was no signiﬁcant diﬀerence in X inactivation pat-
tern when patients were grouped by age (p = 0.69).
We were able to determine which allele carried the GJB1
mutation and had CMTES data for 30 females (Table 1).
When CMTES was plotted against the percentage of
mutant allele that was active, there was no association
between the two (r = 0.33, p = 0.07) (Fig. 2). In addition,
within and between individual families, the percentage of
mutant allele that was active did not correlate with CMT
severity (Fig. 3).
Table 1
Data for 30 females demonstrating percent-
age of mutant-carrying allele that is active
and CMTES.
% Mutant allele active CMTES
2.68 4
3.56 6
18.82 2
20.09 1
20.79 5
29.93 14
31.52 12
33.95 6
35.20 0
43.98 4
44.59 7
44.95 13
45.81 0
51.69 2
53.12 7
54.89 10
57.85 4
58.83 4
63.63 1
64.76 12
64.97 3
66.71 19
72.89 18
76.28 2
76.85 12
77.04 5
78.63 15
86.59 5
86.97 10
88.78 14
CMTES = CMT examination score (max
score 28).
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Fig. 2. Graph demonstrates no signiﬁcant correlation (r = 0.33, p = 0.07)
between the percentage mutant allele which is active in blood and the
CMT Examination Score (CMTES) (n = 30).
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The phenotypic diﬀerence between males and females
with CMT1X is well recognised [8,16]. This has been sug-
gested to occur due to the presence of a non-mutated X
chromosome in females [16]. We previously demonstratedthat males with CMT1X have a relatively uniform pheno-
type [5] while females with CMT1X have variable pheno-
types, ranging from asymptomatic to as severely aﬀected
as males [6]. This variable phenotype in females has been
postulated to occur due to X inactivation.
Carrying a mutation in some X-linked genes has been
demonstrated to aﬀect X inactivation pattern: in X-linked
adrenoleukodystrophy, there is skewing in favour of the
mutant X chromosome [14,17], while mutations in dysto-
nia-deafness-peptide 1 cause skewing in favour of the nor-
mal X chromosome [12]. In addition, the pattern of X
inactivation has been shown to correlate with phenotype
in some X-linked diseases: two sisters were described with
fragile X-associated tremor ataxia syndrome (FXTAS) in
whom the severity of disease correlated with the pattern
of X inactivation [18]. However, a correlation between phe-
notype and X inactivation pattern has not been demon-
strated in other X-linked diseases such as Rett syndrome
[19,20], haemophilia [21] or Duchenne’s muscular dystro-
phy [22]. Only one study has investigated X inactivation
in CMT1X: Lin et al. investigated X inactivation pattern
in blood in the asymptomatic mutation-carrying mother
of a severely aﬀected girl with CMT1X and demonstrated
that the X inactivation pattern was skewed in favour of
the normal allele in the mother; however, they were unable
to determine the X inactivation pattern in the daughter due
to the methodology used [23].
We previously demonstrated in a small cohort that there
was no diﬀerence in X inactivation pattern between females
with CMT1X and controls [6]; this current study conﬁrms
the normal distribution of X inactivation pattern in females
with a GJB1mutation. In addition, this study demonstrates
that there is no correlation between X inactivation pattern
in blood and phenotype. However, given that the pheno-
type in CMT1X is thought to be related to a dosage eﬀect
[5], it may be that X inactivation pattern within Schwann
cells partly explains the variable phenotype in females. Sev-
eral studies have shown that the X inactivation pattern in
diﬀerent tissues does not correlate well [24,25]. Comparison
of X inactivation pattern has not been performed between
blood and peripheral nerve; however, X inactivation pat-
tern between blood (mesodermal origin) and brain tissue
(ectodermal origin) can vary considerably in individuals
[24]. Thus, X inactivation pattern in myelinating Schwann
cells (ectodermal origin) may also be diﬀerent from that in
blood. X inactivation pattern was investigated in blood and
tissue from ﬁve discrete areas of the liver in a female man-
ifesting ornithine transcarbamylase deﬁciency. The authors
found that X inactivation pattern varied between diﬀerent
areas of liver and the pattern in blood diﬀered from that in
liver. However, enzyme activity in each liver sample corre-
lated with X inactivation pattern within that sample [26].
This demonstrates the patchy nature of X inactivation even
within a single tissue but supports the hypothesis that
X inactivation pattern in the tissue of interest may explain
the phenotype in X-linked diseases. Also supporting this
hypothesis, in teased nerve ﬁbres of heterozygous
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Fig. 3. Pedigrees of families demonstrating percentage of mutant allele that is active and CMTES.
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apposed paranodes where one paranode stained for conn-
exin32 while the apposed paranode did not, indicating that
GJB1 was subject to X inactivation in mice and that X
inactivation was patchy within peripheral nerve tissue [7].
Although diﬀerential X inactivation pattern in Schwann
cells may be one possible explanation for the variable phe-
notype in females with GJB1 mutations, we cannot dis-
count other genetic or environmental factors that may
impact on phenotype expression.
In conclusion, females with GJB1 mutations have a nor-
mal distribution of X inactivation pattern and X inactiva-
tion pattern in blood does not correlate with phenotype.
However, we hypothesise that the X inactivation pattern
in the myelinating Schwann cells of peripheral nerves
may account, at least in part, for the variable phenotype
in females with CMT1X.Acknowledgements
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